1-Methyl-1H-benzimidazol-6-amine → N-{2-[2-(3-Methyl-3H-benzoimidazol-5-ylamino)-pyrrolo[2,1-f][1,2,4]triazin-7-yl]-phenyl}-methanesulfonamide

Participants

Reaction Steps

Following the synthetic and purification procedures described in Example 1293d, N-[2-(2-methanesulfinyl-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-phenyl]-methanesulfonamide (56 mg, 0.16 mmol) was coupled with 3-methyl-3H-benzimidazol-5-ylamine (40 mg, 0.28 mmol) at 105° C. for 86 h to afford the title compound. Yield of TFA salt: 19 mg (22%) of brown powder; LC/MS: 434 (M+H); HPLC: 95% pure, RT=2.19 min; 1H NMR: (DMSO, δ) 10.01 (s, 1H), 9.92 (s, 1H), 9.33 (s, 1H), 9.08 (s, 1H), 8.40 (s, 1H), 7.93 (d, J=7.7, 1H), 7.80 (m, 1H), 7.77 (d, J=9.0, 1H), 7.71 (d, J=9.0, 1H), 7.55 (t, J=7.8, 1H), 7.29 (d, J=7.9, 1H), 7.09 (d, J=4.8, 1H), 7.03 (d, J=4.8, 1H), 3.84 (s, 3H), 3.01 (s, 3H).

Provenance & Evidence